U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032
Overview
The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is expected to reach a 4.80 USD Billion by 2032 and is projected to grow at a CAGR of 16.02% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.99
Forecast, 2032 (USD Billion)
4.80
CAGR, 2024 - 2032
16.02%
Report Coverage
U.S.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market 2018-2032 USD Billion
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.99 USD Billion
- Projected Market Size (2032): 4.80 USD Billion
- CAGR (2025-2032): 16.02%
Key Findings of U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market
- The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at 1.99 USD Billion in 2024.
- The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is likely to grow at a CAGR of 16.02% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral in Route of Administration Segment accounted for the largest share of the market with a revenue of 1.23 USD Billion
- The fastest growing segment Direct Tender in Distribution Channel Segment grew Fastest with a CAGR of 17.87% during the forecast period from 2024 to 2032.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Scope
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segmentation & Scope
Distribution Channel
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Direct Tender
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Type
- Others
- Tocilizumab
- Extracorporeal Membrane Oxygenation (ECMO)
- Antiviral Medication
- Corticosteroids
- Mechanical Ventilation
Cause
- Others
- Severe Pneumonia
- Inhalation of Harmful Substances
- Sepsis
Route of Administration
- Others
- Oral
- Parenteral
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.99 USD Billion |
| Market Value in 2032 | 4.80 USD Billion |
| CAGR (2025-2032) | 16.02% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Type,Cause ,Route of Administration |
Regional Insights:
-
Leading Market (2024-2032): U.S., leading in terms of revenue 1.99 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 1,986.25 USD Million in 2024.
Segments and Scope
-
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 774.42 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 17.87 % in forecast period 2025-2032.
-
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By End User
- Hospitals is the largest segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 1.17 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 16.53 % in forecast period 2025-2032.
-
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Type
- Mechanical Ventilation is the largest segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 660.90 USD Billion in the year 2024.
- Mechanical Ventilation is the Fastest growing segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 17.83 % in forecast period 2025-2032.
-
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Cause
- Sepsis is the largest segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 971.30 USD Billion in the year 2024.
- Sepsis is the Fastest growing segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 17.55 % in forecast period 2025-2032.
-
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Route of Administration
- Parenteral is the largest segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 1.23 USD Billion in the year 2024.
- Parenteral is the Fastest growing segment in U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 16.99 % in forecast period 2025-2032.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Share Analysis
| Company Name |
|
||
| Medtronic | |||
| LivaNova | |||
| Terumo Corporation | |||
| Getinge AB | |||
| Gilead Sciences, Inc. | |||
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Geographical Sales Distribution, 2018-2032 USD Billion
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Distribution Channel,End User,Type,Cause ,Route of Administration .
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 1.99(Revenue in USD Billion) in 2021.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 16.02% during the forecast period of 2024 to 2032.
The Parenteral segment is expected to dominate the U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market, holding a largest market share of 1.23 USD Billion in 2024
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Scope
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segmentation & Scope
Distribution Channel
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Direct Tender
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Type
- Others
- Tocilizumab
- Extracorporeal Membrane Oxygenation (ECMO)
- Antiviral Medication
- Corticosteroids
- Mechanical Ventilation
Cause
- Others
- Severe Pneumonia
- Inhalation of Harmful Substances
- Sepsis
Route of Administration
- Others
- Oral
- Parenteral
Frequently Asked Questions
The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Distribution Channel,End User,Type,Cause ,Route of Administration .
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 1.99(Revenue in USD Billion) in 2021.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 16.02% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market for final year is USD 4.80 (USD Billion).
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Profiling
Frequently Asked Questions
The U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Distribution Channel,End User,Type,Cause ,Route of Administration .
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 1.99(Revenue in USD Billion) in 2021.
U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 16.02% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Acute Respiratory Distress Syndrome (ARDS) Treatment Market for final year is USD 4.80 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.